Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD 490.00
-53.00 (-9.76%)
At close: Feb 11, 2026
Bora Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 21,097 | 19,246 | 14,200 | 10,494 | 4,900 | 1,800 | |
Revenue Growth (YoY) | 36.05% | 35.53% | 35.31% | 114.18% | 172.28% | 17.68% |
Cost of Revenue | 13,117 | 11,536 | 7,209 | 7,582 | 3,228 | 1,096 |
Gross Profit | 7,980 | 7,710 | 6,991 | 2,913 | 1,672 | 703.88 |
Selling, General & Admin | 4,100 | 3,633 | 1,444 | 861.52 | 584.52 | 441.16 |
Research & Development | 769.93 | 694.49 | 298.16 | 129.08 | 41.27 | 36.65 |
Operating Expenses | 4,871 | 4,328 | 1,742 | 990.6 | 625.79 | 477.81 |
Operating Income | 3,110 | 3,383 | 5,249 | 1,922 | 1,046 | 226.08 |
Interest Expense | -484.23 | -479.72 | -171.24 | -108.73 | -53.62 | -21.97 |
Interest & Investment Income | 36.36 | 91.42 | 62.95 | 11.36 | 0.22 | 0.96 |
Earnings From Equity Investments | -305.9 | -0.04 | - | - | - | - |
Currency Exchange Gain (Loss) | -85.36 | 163.52 | -67.51 | 47.92 | -14.41 | -11.91 |
Other Non Operating Income (Expenses) | 8.5 | 64.53 | 39.98 | 17.41 | 48.02 | 14.28 |
EBT Excluding Unusual Items | 2,279 | 3,222 | 5,113 | 1,890 | 1,026 | 207.43 |
Gain (Loss) on Sale of Investments | 2,522 | 11.56 | -1,044 | -47.79 | - | 0.11 |
Gain (Loss) on Sale of Assets | -27.99 | -27.99 | -5 | -2.36 | -2.24 | -0 |
Other Unusual Items | 86.5 | 1,749 | - | - | - | 387.86 |
Pretax Income | 4,860 | 4,955 | 4,064 | 1,840 | 1,024 | 595.4 |
Income Tax Expense | 561.97 | 914.58 | 992.23 | 438.48 | 274.23 | 16.97 |
Earnings From Continuing Operations | 4,298 | 4,040 | 3,072 | 1,402 | 749.74 | 578.43 |
Minority Interest in Earnings | -56.02 | -101.39 | -41.78 | -9.61 | - | - |
Net Income | 3,081 | 3,939 | 3,030 | 1,392 | 749.74 | 578.43 |
Net Income to Common | 3,081 | 3,939 | 3,030 | 1,392 | 749.74 | 578.43 |
Net Income Growth | -24.35% | 29.99% | 117.70% | 85.65% | 29.62% | 89.63% |
Shares Outstanding (Basic) | 124 | 122 | 120 | 117 | 116 | 115 |
Shares Outstanding (Diluted) | 136 | 134 | 124 | 118 | 117 | 116 |
Shares Change (YoY) | 2.02% | 8.17% | 4.93% | 1.41% | 0.86% | 7.55% |
EPS (Basic) | 24.85 | 32.25 | 25.17 | 11.89 | 6.44 | 5.03 |
EPS (Diluted) | 24.04 | 29.86 | 24.50 | 11.78 | 6.42 | 5.00 |
EPS Growth | -22.32% | 21.90% | 107.94% | 83.40% | 28.53% | 76.28% |
Free Cash Flow | 2,090 | 452.71 | 4,316 | 1,815 | 1,073 | 28.56 |
Free Cash Flow Per Share | 15.42 | 3.37 | 34.74 | 15.33 | 9.19 | 0.25 |
Dividend Per Share | 11.669 | 11.669 | 10.002 | 5.133 | 2.041 | 0.936 |
Dividend Growth | 16.67% | 16.67% | 94.84% | 151.53% | 118.14% | 30.00% |
Gross Margin | 37.83% | 40.06% | 49.23% | 27.76% | 34.12% | 39.11% |
Operating Margin | 14.74% | 17.58% | 36.97% | 18.32% | 21.35% | 12.56% |
Profit Margin | 14.60% | 20.47% | 21.34% | 13.26% | 15.30% | 32.14% |
Free Cash Flow Margin | 9.90% | 2.35% | 30.39% | 17.30% | 21.90% | 1.59% |
EBITDA | 4,082 | 4,240 | 5,734 | 2,169 | 1,211 | 354.25 |
EBITDA Margin | 19.35% | 22.03% | 40.38% | 20.67% | 24.72% | 19.68% |
D&A For EBITDA | 972.47 | 857.49 | 485.11 | 246.69 | 165.27 | 128.17 |
EBIT | 3,110 | 3,383 | 5,249 | 1,922 | 1,046 | 226.08 |
EBIT Margin | 14.74% | 17.58% | 36.97% | 18.32% | 21.35% | 12.56% |
Effective Tax Rate | 11.56% | 18.46% | 24.41% | 23.83% | 26.78% | 2.85% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.